Apnimed Stock (NASDAQ:APMD)
Previous Close
$18.22
52W Range
$16.00 - $35.29
50D Avg
$26.07
200D Avg
$26.07
Market Cap
$737.53M
Avg Vol (3M)
$552.07K
Beta
-
Div Yield
-
APMD Company Profile
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.